Multi-nanocarrier Strategy for Light-Activated Nitric Oxide Release: Ruthenium Nitrosyl Complexes in Liposomes, Micelles, and Niosomes for Cancer Therapy

Nitric oxide (NO), once regarded solely as an atmospheric pollutant, is now widely recognized for its important therapeutic functions in biological systems. However, several challenges limit its direct medical use, such as its short half-life, the non-biocompatibility of several NO donors, and their uncontrolled release patterns. To address these challenges, a series of nanomaterials, including vesicles, micelles, and niosomes, have been developed to incorporate a newly synthesized amphiphilic ruthenium nitrosyl (Ru-NO) complex as a versatile photoactivatable NO donor. Notably, this is the first report of encapsulating this amphiphilic Ru-NO complex designated as <b>1·NO</b>, in niosomes (termed <b>1·NO-Nio</b>) for phototriggered NO delivery. The release kinetics and quantum yield of <b>1·NO</b>, as well as its nanoencapsulated forms <b>1·NO-Ves</b>, <b>1·NO-Mic</b>, and <b>1·NO-Nio</b>, were evaluated using UV-vis spectroscopy, Griess assay, and 4-amino-5-methylamino-2',7'-difluorescein diacetate (DAF-FM DA) fluorescence under blue light irradiation (420 nm). Free <b>1·NO</b> released a significant amount of NO (11 μM), whereas encapsulation within nanocarriers resulted in a more controlled and prolonged NO release, with release rates (<i>k</i><sub>NO</sub>) of 0.0093, 0.0065, and 0.0025 min<sup>-1</sup> for <b>1·NO-Ves</b>, <b>1·NO-Mic</b>, and <b>1·NO-Nio</b>, respectively. All three nanocarrier-based nitric oxide (NO) delivery systems demonstrated pronounced, light-activated anticancer activity in vitro tests against the 4T1 breast cancer cell line, with the liposome-based formulation (<b>1·NO-Ves</b>) exhibiting the strongest therapeutic efficacy. These results underscore how distinct nanomaterial platforms can have a significant influence on the nitric oxide (NO) release behavior of a photocontrollable ruthenium nitrosyl (Ru-NO) complex. This underlines the critical role of nanocarrier design in optimizing the performance of photoactivated NO donors for cancer therapy.

Authors

Institutions

Publication Details

Journal
ACS Applied Bio Materials
Published
2025-10-27
DOI
https://doi.org/10.1021/acsabm.5c01415
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multi-nanocarrier Strategy for Light-Activated Nitric Oxide Release: Ruthenium Nitrosyl Complexes in Liposomes, Micelles, and Niosomes for Cancer Therapy

Vinod Kumar, Priyanka Sharma, Nancy Sharma, Asifkhan Shanavas et al.
ACS Applied Bio Materials
Nanoplatforms for cancer theranostics
article

Multi-nanocarrier Strategy for Light-Activated Nitric Oxide Release: Ruthenium Nitrosyl Complexes in Liposomes, Micelles, and Niosomes for Cancer Therapy

Vinod Kumar, Priyanka Sharma, Nancy Sharma, Asifkhan Shanavas, D. Amilan Jose, Nitin Nitin
article en

Abstract

Nitric oxide (NO), once regarded solely as an atmospheric pollutant, is now widely recognized for its important therapeutic functions in biological systems. However, several challenges limit its direct medical use, such as its short half-life, the non-biocompatibility of several NO donors, and their uncontrolled release patterns. To address these challenges, a series of nanomaterials, including vesicles, micelles, and niosomes, have been developed to incorporate a newly synthesized amphiphilic ruthenium nitrosyl (Ru-NO) complex as a versatile photoactivatable NO donor. Notably, this is the first report of encapsulating this amphiphilic Ru-NO complex designated as <b>1·NO</b>, in niosomes (termed <b>1·NO-Nio</b>) for phototriggered NO delivery. The release kinetics and quantum yield of <b>1·NO</b>, as well as its nanoencapsulated forms <b>1·NO-Ves</b>, <b>1·NO-Mic</b>, and <b>1·NO-Nio</b>, were evaluated using UV-vis spectroscopy, Griess assay, and 4-amino-5-methylamino-2',7'-difluorescein diacetate (DAF-FM DA) fluorescence under blue light irradiation (420 nm). Free <b>1·NO</b> released a significant amount of NO (11 μM), whereas encapsulation within nanocarriers resulted in a more controlled and prolonged NO release, with release rates (<i>k</i><sub>NO</sub>) of 0.0093, 0.0065, and 0.0025 min<sup>-1</sup> for <b>1·NO-Ves</b>, <b>1·NO-Mic</b>, and <b>1·NO-Nio</b>, respectively. All three nanocarrier-based nitric oxide (NO) delivery systems demonstrated pronounced, light-activated anticancer activity in vitro tests against the 4T1 breast cancer cell line, with the liposome-based formulation (<b>1·NO-Ves</b>) exhibiting the strongest therapeutic efficacy. These results underscore how distinct nanomaterial platforms can have a significant influence on the nitric oxide (NO) release behavior of a photocontrollable ruthenium nitrosyl (Ru-NO) complex. This underlines the critical role of nanocarrier design in optimizing the performance of photoactivated NO donors for cancer therapy.

ACS Applied Bio MaterialsVol. 8(11)
National Institute of Technology Kurukshetra (IN), Institute of Nano Science and Technology
Openalex Percentile: Top 70%
Nanoplatforms for cancer theranostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.